Monoclonal gammopathy of undetermined significance;Les gammapathies monoclonales de signification indéterminée

Annales de Medecine Interne

Volumn 153, Issue 7, 2002, Pages 459-466

  Chaïbi, Pascal ^a,b   Merlin, Laurence ^c   Thomas, Caroline ^a   Piette, François ^a  

^a HÔPITAL CHARLES FOIX   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Gériatre ^*  (France)

Author keywords

Elderly; Monoclonal gammopathy; Multiple myeloma

Indexed keywords

PARAPROTEIN;

CLINICAL FEATURE; CYTOGENETICS; DATA ANALYSIS; DISEASE COURSE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR BIOLOGY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PREDICTION; PREVALENCE; REVIEW; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; SURVIVAL ANALYSIS;

EID: 17744414996     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Kyle RA, Rakjumar SV: Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am, 1999; 13: 1181-202.
2. Zandecki M, Genevieve F, Jego P, Grosbois B: Les gammapathies monoclonales de signification indéterminée. Rev Med Interne, 2000; 21: 1060-74.
3. Kyle RA: Monoclonal gammopathy of undetermined significance and solitary plasmocytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am, 1997; 11: 71-87.
4. Ong F, Hermans J, Noordijk EM, et al.: A population-based registry on paraproteinaemia in the Netherlands. Br J Haematol, 1997; 99: 914-20.
5. Baldini L, Guffanti A, Cesana BM: Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood, 1996; 87: 912-9.
6. Vuckovic J, Ilic A, Knezevic N, et al.: Prognosis in monoclonal gammopathy of undetermined significance. Br J Haematol, 1997; 97: 649-51.
7. Bataille R, Chappard D, Basle MF: Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. Blood, 1996; 87: 4762-9.
8. Abildgaard N, Glerup H, Rungby J, et al.: Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol, 2000; 64: 121-9.
9. Corso A, Arcaini L, Mangiacavalli S, et al.: Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica, 2001; 86: 394-8.
10. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M: Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem, 2001; 47: 686-93.
11. Woitge HW, Pecherstorfer M, Horn E, et al.: Serum bone sialoprotein as a marker of tumour burden and neoplastic involvement and as a prognostic factor in multiple myeloma. Br J Cancer, 2001; 84: 344-51.
12. Seibel MJ, Woitge HW, Pecherstorfer M, et al.: Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab, 1996; 81: 3289-94.
13. Anderson KC, Lust JA: Role of cytokines in multiple myeloma. Semin Hematol, 1999; 36: 14-20.
14. Donovan KA, Lacy MQ, Kline MP, et al.: Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia, 1998; 12: 593-600.
15. Lacy MQ, Donovan A, Heimbach JK, Ahmann GJ, Lust JA: Comparison of interleukin-1β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood, 1999; 93: 300-5.
16. Almeida J, Orfao A, Mateo G, et al.: Immunophenotypic and DNA content characteristics in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol Biol, 1999; 47: 119-27.
17. Avet-Loiseau H, Li JY, Morineau N, et al.: Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood, 1999; 94: 2583-9.
18. Avet-Loiseau H, Facon T, Daviet A, et al.: 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Res, 1999; 59: 4546-50.
19. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL: Multiple Myeloma. American Society of Hematology, Educational Book, 2001: 157-77.
20. Fonseca R, Oken MM, Greipp PR, et al.: The t (4;14) (p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood, 2001; 98: 1271-2.
21. Davies FE, Jack AS, Morgan GJ: The use of biological variables to predict outcome in multiple myeloma. Br J Haematology, 1997; 99: 719-25.
22. INK4b gene methylation in plasma cells from monoclonal gammopathy of undetermined significance. Blood, 2001; 98: 244-6.
23. Ackermann J, Meidlinger P, Zojer N, et al.: Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol, 1998; 103: 1161-3.
24. Ghia P, Melchers F, Rolink AG: Age-dependent changes in B lymphocyte development in man and mouse. Exp Gerontol, 2000; 35: 159-65.